Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.
Sponsor: Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
Summary
The main purpose of this study is to evaluate the effectiveness of technetium \[99mTc\]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To evaluate the safety of technetium \[99mTc\]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To explore the diagnostic threshold of technetium \[99mTc\]-H7ND injection for peritoneal metastasis of gastrointestinal malignant tumor.
Official title: A Multicenter, Open-access, Self-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mTc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignancies.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2025-03-12
Completion Date
2025-09
Last Updated
2025-08-06
Healthy Volunteers
No
Conditions
Interventions
Technetium [99mTc]-H7ND injection
Technetium \[99mTc\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor
Locations (1)
Zhongshan Hospital Affiliated to Fudan University
Shanghai, China